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Objectives The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)–lowering efficacy of
5 SAR236553/REGN727 (SAR236553) dosing regimens versus placebo at week 12 in patients with LDL-C 100
mg/dl on stable atorvastatin therapy. Secondary objectives included evaluation of effects on other lipid parameters
and the attainment of LDL-C treatment goals of100mg/dl (2.59 mmol/l) and70mg/dl (1.81 mmol/l).
Background Serum proprotein convertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprotein receptors, increasing
serum LDL-C. SAR236553 is a fully human monoclonal antibody to PCSK9.
Methods This double-blind, parallel-group, placebo-controlled trial randomized 183 patients with LDL-C 100 mg/dl (2.59
mmol/l) on stable-dose atorvastatin 10, 20, or 40 mg for 6 weeks to: subcutaneous placebo every 2 weeks
(Q2W); SAR236553 50, 100, or 150 mg Q2W; or SAR236553 200 or 300 mg every 4 weeks (Q4W), alternating
with placebo for a total treatment period of 12 weeks.
Results SAR236553 demonstrated a clear dose-response relationship with respect to percentage LDL-C lowering for both
Q2W and Q4W administration: 40%, 64%, and 72% with 50, 100, and 150 mg Q2W, respectively, and 43% and 48%
with 200 and 300 mg Q4W. LDL-C reduction with placebo at week 12 was 5%. SAR236553 also substantially re-
duced non–high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a). SAR236553 was generally well
tolerated. One patient on SAR236553 experienced a serious adverse event of leukocytoclastic vasculitis.
Conclusions When added to atorvastatin, PCSK9 inhibition with SAR236553 further reduces LDL-C by 40% to 72%. These addi-
tional reductions are both dose- and dosing frequency–dependent. (Efficacy and Safety Evaluation of SAR236553
[REGN727] in Patients With Primary Hypercholesterolemia and LDL-cholesterol on Stable Atorvastatin Therapy;
NCT01288443) (J Am Coll Cardiol 2012;59:2344–53) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.03.007Cardiovascular disease remains the leading cause of death in
most Western nations, and is increasing rapidly in the
developing world. Reduction of low-density lipoprotein
cholesterol (LDL-C), especially with statins, is widely
recognized as the single most effective intervention to
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June 19/26, 2012:2344–53 Safety and Efficacy of SAR236553/REGN727levels of LDL-C lowering and cardioprotective benefits
(5–9). Accordingly, current U.S., Canadian, and European
treatment guidelines advocate decreasing LDL-C to 70
mg/dl in patients at very high risk (2–4). Within-trial
analyses indicate that greater risk reduction may be achieved
with even lower LDL-C levels, and indicate no association of
these lower LDL-C levels with increased incidences of
adverse events (AEs) (10–13).
Despite the proven cardioprotective effects of statins,
many patients fail to reach recommended LDL-C targets in
clinical practice, even with the addition of cholesterol
absorption inhibitors, niacin, or bile acid resins to a statin
(14,15).
Proprotein convertase subtilisin/kexin type 9 serine pro-
tease (PCSK9) plays a pivotal role in low-density lipopro-
tein receptor (LDLR) degradation. Gain-of-function mu-
tations of PCSK9 in humans result in hypercholesterolemia
(16,17), whereas loss-of-function mutations are associated
with low LDL-C and significantly reduced cardiovascular
risk (18).
SAR236553/REGN727 (SAR236553) is a highly spe-
cific, fully human monoclonal antibody to PCSK9 that, in
proof-of-concept trials in familial and non-familial hyper-
cholesterolemia, dose-dependently reduced LDL-C by up
to 62% from baseline, either with or without atorvastatin
(19–21). The current phase 2 trial assessed 5 different
SAR236553 dose regimens in patients with LDL-C 100
mg/dl while receiving stable 10-, 20-, or 40-mg atorvastatin
doses.
Methods
This double-blind, parallel-group, placebo-controlled, US
multicenter trial included patients with LDL-C 100
mg/dl (2.59 mmol/l) on stable-dose atorvastatin 10 mg, 20
mg, or 40 mg for 6 weeks. All patients reviewed and
igned an informed consent form approved by a local or
entral institutional review board prior to any study-related
rocedures. Study procedures complied with International
onference on Harmonization Good Clinical Practice
uidelines. An independent data monitoring committee
onitored patient safety.
The primary objective was to evaluate the effect of 12
eeks treatment with SAR236553 versus placebo on
DL-C. Other objectives reported here are measurement
f: absolute and/or percentage changes in total cholesterol,
igh-density lipoprotein cholesterol (HDL-C), triglycer-
des, non–HDL-C, apolipoprotein (Apo)-B, Apo-A1, and
ipoprotein a (Lp[a]); and the proportion of patients achiev-
ng LDL-C treatment goals of 100 mg/dl (2.59 mmol/l)
and 70 mg/dl (1.81 mmol/l).
Study population. Eligible subjects were men and non-
pregnant, nonlactating women age 18 to 75 years (inclu-
sive), with LDL-C 100 mg/dl (2.59 mmol/l) while
eceiving a stable dose of atorvastatin 10, 20, or 40 mg daily
or 6 weeks. Drug-naive patients or patients either receiving Slipid-lowering therapy other
han atorvastatin or not on a stable
ose of atorvastatin 10, 20, or 40
g daily for 6 weeks were eligi-
le, provided that they met the
nclusion criteria after discontinu-
ng all other lipid-lowering therapy
nd completing a 6-week run-in of
torvastatin 10, 20, or 40 mg daily.
Females of childbearing po-
ential not using an effective form
f contraceptive, or pregnant or
reastfeeding, were excluded, as
ere individuals with known
ensitivities to monoclonal anti-
ody therapies; type 1 diabetes or
ype 2 diabetes requiring insulin,
r with HbA1c 8.5%; any clin-
ically significant endocrine dis-
ease; blood pressure 150/95
mm Hg; a history of major cor-
onary event within 6 months of
screening; a history of class II to IV heart failure; a positive
serum or urine pregnancy test; a positive test for hepatitis B
or hepatitis C; triglycerides350 mg/dl; abnormal sensitive
thyroid-stimulating hormone level; serum creatinine 1.5
 upper limit of normal (ULN) in men or 1.4  ULN in
women; creatine kinase3 ULN; or alanine aminotrans-
ferase or aspartate aminotransferase 2  ULN.
Non–study-related lipid-altering therapy use was prohib-
ited during the study. Thyroid preparations or thyroxin
treatment (except in patients on replacement therapy) and
insulin treatment were also prohibited. Nutraceutical prod-
ucts that may affect lipids were allowed if used at a stable
dose for 6 weeks prior to and during screening, and if
maintained at a stable dose throughout the study; initiation
during the study of treatment with nutraceuticals that affect
lipids, including 1,000 mg daily of omega-3 fatty acids,
red yeast rice, and plant sterols, was prohibited.
Study design and procedures. The study comprised 3
periods: screening, 12-week double-blind treatment, and
8-week follow-up (Fig. 1). Screening period duration varied
according to atorvastatin treatment status. For patients
already receiving stable-dose atorvastatin 10, 20, or 40 mg
for 6 weeks, the eligibility screening period was 1 week; for
patients requiring the 6-week atorvastatin run-in, screening
was at week 7 with eligibility assessment at week 1.
Visits during the treatment period were every 2 weeks.
atients continued on the same atorvastatin dose and were
andomized 1:1:1:1:1:1 to placebo every 2 weeks (Q2W);
AR236553 50, 100, or 150 mg Q2W; or SAR236553 200
r 300 mg every 4 weeks (Q4W) alternating with placebo to
imic Q2W dosing. Randomization was stratified accord-
ng to atorvastatin dose, to evaluate any effect of background
torvastatin dose on the LDL-C–lowering efficacy of
Abbreviations
and Acronyms
AE  adverse event
Apo  apolipoprotein
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
LDLR  low-density
lipoprotein receptor
Lp(a)  lipoprotein a
mITT  modified
intent-to-treat
PCSK9  proprotein
convertase subtilisin/kexin
type 9 serine protease
Q2W  every 2 weeks
Q4W  every 4 weeks
ULN  upper limit of
normalAR236553. Visits during follow-up were every 4 weeks.
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Safety and Efficacy of SAR236553/REGN727 June 19/26, 2012:2344–53All laboratory samples were processed by Medpace Ref-
erence Laboratories (Cincinnati, Ohio), which maintained
Part III certification by the CDC Lipid Standardization
Program (22) and accreditation by the College of American
Pathologists (23). All lipids, Apos, and safety laboratory
tests were performed after 12-h overnight fasts (water only).
Triglycerides and cholesterol were measured with enzymatic
colorimetric tests (Olympus AU2700 or AU5400 Analyzer,
Olympus, Center Valley, Pennsylvania) with calibration
directly traceable to Centers for Disease Control reference
procedures. Apo-B–containing lipoproteins were precipi-
tated with dextran sulphate, and HDL-C was measured on
the supernatant (24). Apo-A1, Apo-B, and Lp(a) were
measured with rate immunonephelometry (Dade Behring
BNII nephelometer, Siemens Healthcare Diagnostics,
Deerfield, Illinois).
Safety assessments. Safety was assessed throughout the
study by clinical examination, vital signs, AEs, serious AEs,
laboratory tests, and 12-lead electrocardiogram. AE data
were collected from screening onwards.
Statistical methods. The primary study endpoint was the
percentage change in calculated LDL-C from baseline (mean
of week –1 and week 0) to week 12. To detect a 30% difference
in % LDL-C change with SAR236553 versus placebo, assum-
ing a 20% to 30% standard deviation and a 5% rate of
unevaluable primary endpoint, and using a 2-sided t test at 0.05
ignificance level, 30 patients per treatment arm were required
o achieve a power of 96%.
For the primary efficacy endpoint analysis, a hierarchical
esting procedure was applied to ensure strong control of
he overall type-I error rate at the 0.05 level when testing
he 5 SAR236553 dose regimens versus placebo. The order
sed was SAR236553 150 mg Q2W versus placebo first;
AR236553 300 mg Q4W versus placebo second;
AR236553 100 mg Q2W third; SAR236553 200 mg
Placebo Q2W
SAR236553 50 m
SAR236553 100
SAR236553 150
SAR236553 200
SAR236553 300
N=31
N=30
N=31
N=31
N=30
N=30
W-7
V1a
W-1
V1
W0
V2
W2
V3
W4
V4
Screening period 7 weeks with 
atorvastatin run-in or 1 week 
without run-in
Randomization
Diet*
Treatment Period (12 
Figure 1 Study Design
Overview of study periods and treatment arms. *NCEP-ATPIII TLC or equivalent die4W fourth; and finally, SAR236553 50 mg Q2W. The fierarchical testing sequence continued only when the
igher-order test was statistically significant at the 5% level.
o further adjustment was performed for secondary analy-
es or endpoints, for which p values were provided for
escriptive purposes only.
EFFICACY ENDPOINTS. The primary efficacy endpoint was
analyzed in the modified intent-to-treat (mITT) popula-
tion, defined as all randomized patients with an evaluable
primary endpoint, using an analysis of covariance model
with treatment group and randomization strata of atorva-
statin dose as fixed effects, and baseline LDL-C as covariate.
The treatment group factor had 6 levels: placebo;
SAR236553 50 mg Q2W; SAR236553 200 mg Q4W;
SAR236553 100 mg Q2W; SAR236553 300 mg Q4W;
and SAR236553 150 mg Q2W. Patients in the mITT
population were analyzed according to the randomized
treatment group. The last observation carried forward
method was applied to impute missing week 12 LDL-C
on-treatment values. Throughout the analysis of covariance
model, each SAR236553 treatment group was compared
with placebo using appropriate contrasts. Ninety-five per-
cent confidence intervals of the difference versus placebo
were not adjusted for multiple comparisons. Secondary
efficacy endpoints were analyzed in the mITT population
using the same analysis of covariance model, with treatment
group and randomization strata of atorvastatin dose as fixed
effect, and corresponding baseline value as covariate.
SAFETY ENDPOINTS. All safety analyses were performed
n the safety population (all randomized patients who
eceived at least 1 full or partial dose of investigational
roduct, analyzed according to the treatment actually
eceived). Four patients received a dose at 1 (or several)
isit(s) differing from the dose allocated (5 cases in 4
atients). For these patients, the treatment arm allocation
W
2W
2W
4W/alternating placebo
4W/alternating placebo
W6
V5
W8
V6
W10
V7
W12
V8
W16
V9
W20
V10
s) Follow-up Period (8 Weeks)
 every 2 weeks; Q4W  every 4 weeks; W  week.g Q2
 mg Q
 mg Q
 mg Q
 mg Q
Week
t. Q2Wor as-treated analysis was defined in a blinded manner
(
n
u
f
e
i
c
P
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June 19/26, 2012:2344–53 Safety and Efficacy of SAR236553/REGN727using a pre-specified algorithm before the database was
locked. Demographic and baseline data were summarized
on the all-randomized population, and analyzed in the
randomized treatment group.
Results
Study population. Of 514 patients screened at 34 centers
between January 2011 and August 2011, 183 met the
eligibility criteria and were randomized to treatment (Fig. 2).
Ninety percent of patients completed the full 12-week
treatment period. The most frequent cause of premature
Enrollment
F
A
Screening
Random
Allocated to placebo Q2W (n = 31)
 • Randomized and 
  treated (n = 31)
 • Completed treatment 
  period (n = 31)
 • Did not complete treatment 
  period (n = 0)  
Allocated to SAR236553 50 mg 
Q2W (n = 30)
 • Randomized and 
  treated (n = 30)
 • Completed treatment 
  period (n = 29)
 • Did not complete 
  treatment period (n = 1)  
Allocated to SAR236553 100 mg 
Q2W (n = 31) 
 • Randomized and 
  treated (n = 31)
 • Completed treatment
  period (n = 30)
 • Did not complete 
  treatment period (n = 1)  
Lost to follow-up (n = 0) 
Discontinued intervention (n = 0) 
Lost to follow-up (n = 1) 
Discontinued intervention (n = 1) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 1) 
Included in efficacy analysis (n = 31)
Excluded from efficacy analysis (n = 0) 
Included in efficacy analysis (n = 30)
Excluded from efficacy analysis (n = 0) 
Included in efficacy analysis (n = 31)
Excluded from efficacy analysis (n = 
Figure 2 Patient Disposition
Numbers of patients included and excluded at each stage of the study.
Patient Demographic and Baseline Characteristics by Assigned TreTable 1 Patient Demographic and Baseline Characteristics by
Placebo
(n  31)
50 mg Q2W
(n  30)
Age, yrs 53.3 8.5 58.5 9.1
Female 15 (48.4) 13 (43.3)
Race*
White 27 (87.1) 26 (86.7)
Black 3 (9.7) 4 (13.3)
Other 1 (3.2) 0 (0.0)
Hispanic or Latino ethnicity 7 (22.6) 5 (16.7)
BMI, kg/m2 27.9 4.8 30.0 4.5
Years since diagnosis of hyperlipoproteinemia 10.1 8.8 10.3 8.7
Previous treatment with a lipid-lowering agent 25 (80.6) 25 (83.3)
Hypertension 11 (35.5) 16 (53.3)
Type 2 diabetes 1 (3.2) 3 (10.0)
Coronary artery disease 2 (6.5) 2 (6.7)
Cerebrovascular disease 0 (0.0) 0 (0.0)
Peripheral vascular disease 0 (0.0) 0 (0.0)
Current smoker† 8 (25.8) 5 (16.7)Values are mean  SD or n (%). *Patients may be included in more than 1 category. †Patients who have
BMI  body mass index; Q2W  every 2 weeks; Q4W  every 4 weeks.study withdrawal (n  6) was treatment-emergent AEs
described later in the text). Other causes included
oncompliance with study medication, difficulty with/
nacceptability of subcutaneous injections, and loss to
ollow-up (Fig. 2).
Table 1 summarizes baseline patient characteristics. The
fficacy analysis included 179 patients (98%). One random-
zed patient was not treated; the safety population therefore
omprised 182 patients.
rimary efficacy outcomes. Table 2 summarizes changes
n lipid values from baseline to week 12. Mean baseline
 = 514) 
 183) 
Excluded (n = 331)
 • Did not meet inclusion criteria (n = 306)
 • Withdrew consent (n = 22)
 • Adverse events (n = 3)  
ocated to SAR236553 150 mg
W (n = 31) 
• Randomized and 
 treated (n = 31)
• Completed treatment 
 period (n = 27)
• Did not complete 
 treatment period (n = 4)  
Allocated to SAR236553 200 mg 
Q4W (n = 30)
 • Randomized and 
  treated (n = 29)
 • Completed treatment 
  period (n = 23)
 • Did not complete 
  treatment period (n = 6)  
Allocated to SAR236553 300 mg
 Q4W (n = 30)
 • Randomized and 
  treated (n = 30)
 • Completed treatment 
  period (n = 25)
 • Did not complete 
  treatment period (n = 5)  
st to follow-up (n = 0) 
continued intervention (n = 4) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 6) 
Lost to follow-up (n = 0)
Discontinued intervention (n = 5) 
ded in efficacy analysis (n = 29)
luded from efficacy analysis (n = 2) 
Included in efficacy analysis (n = 28)
Excluded from efficacy analysis (n = 2)
Included in efficacy analysis (n = 30)
Excluded from efficacy analysis (n = 0) 
nt Group (Randomized Population)ned Treatment Group (Randomized Population)
g Q2W
31)
150 mg Q2W
(n  31)
200 mg Q4W
(n  30)
300 mg Q4W
(n  30)
All
(N  183)
 9.2 59.9 11.1 54.9 10.8 55.5 10.1 56.7 10.0
(58.1) 21 (67.7) 13 (43.3) 16 (53.3) 96 (52.5)
(77.4) 25 (80.6) 28 (93.3) 28 (93.3) 158 (86.3)
(19.4) 6 (19.4) 2 (6.7) 2 (6.7) 23 (12.6)
(3.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
(12.9) 7 (22.6) 9 (30.0) 8 (26.7) 40 (21.9)
 4.4 28.2 4.3 29.1 4.2 30.5 6.0 29.2 4.8
 7.5 9.2 10.1 7.7 6.5 8.4 6.7 9.2 8.1
(90.3) 27 (87.1) 26 (86.7) 27 (90.0) 158 (86.3)
(61.3) 14 (45.2) 9 (30.0) 13 (43.3) 82 (44.8)
(6.5) 3 (9.7) 4 (13.3) 9 (30.0) 22 (12.0)
(3.2) 2 (6.5) 2 (6.7) 1 (3.3) 10 (5.5)
(3.2) 0 (0.0) 2 (6.7) 0 (0.0) 3 (1.6)
(0.0) 3 (9.7) 1 (3.3) 1 (3.3) 5 (2.7)
(9.7) 9 (29.0) 4 (13.3) 8 (26.7) 37 (20.2)ollow-up 
Analysis
llocation 
/run-in (n
ized (n =
All
Q2
 
 
 
 
 
 
Lo
Dis
0) 
Inclu
ExcatmeAssig
100 m
(n 
58.1
18
24
6
1
4
29.3
9.5
28
19
2
1
1
0
3smoked 1 cigarette, as a mean, per day during the past 7 days.
Changes in Lipid Parameters From Baseline to Week 12 by Treatment Group (mITT Population)Table 2 Changes in Lipid Parameters From Baseline to Week 12 by Treatment Group (mITT Population)
SAR236553
Placebo
(n  31)
50 mg Q2W
(n  30)
100 mg Q2W
(n  31)
150 mg Q2W
(n  29)
200 mg Q4W
(n  28)
300 mg Q4W
(n  30)
LDL-C, mg/dl
Baseline 130.2 27.3 123.2 27.9 127.0 30.4 123.9 26.7 128.2 19.2 131.6 24.8
Week 12 120.5 27.0 73.2 16.4 46.0 24.4 34.2 15.6 71.1 21.6 66.0 27.7
% Change from baseline to week 12, LS mean* (SE) –5.1 (3.1) –39.6 (3.2) –64.2 (3.1) –72.4 (3.2) –43.2 (3.3) –47.7 (3.2)
p Value* for % change with SAR236553 vs. placebo 0.0001† 0.0001† 0.0001† 0.0001† 0.0001†
TC, mg/dl
Baseline 209.0 27.9 203.3 28.1 203.0 31.4 205.2 29.7 204.2 25.4 207.1 30.2
Week 12 203.1 35.5 155.1 21.7 122.7 26.7 111.1 20.7 146.0 25.9 143.0 31.6
% Change from baseline to week 12, LS mean* (SE) 1.6 (2.3) 23.0 (2.3) 39.7 (2.3) 45.2 (2.3) 28.0 (2.4) 29.8 (2.3)
p Value* for % change with SAR236553 vs. placebo 0.0001 0.0001 0.0001 0.0001 0.0001
HDL-C, mg/dl
Baseline 49.0 (10.3) 53.8 (13.6) 52.6 (13.0) 53.3 (16.1) 46.7 (10.8) 48.0 (13.8)
Week 12 48.9 (13.2) 56.8 (14.4) 54.5 (15.4) 55.1 (14.8) 49.4 (10.5) 51.7 (15.6)
% Change from baseline to week 12, LS mean* (SE) –1.0 (2.3) 6.7 (2.4) 4.1 (2.3) 5.5 (2.4) 6.3 (2.5) 8.5 (2.4)
p Value* for % change with SAR236553 vs. placebo 0.0218 0.1247 0.0570 0.0320 0.0047
TG, mg/dl
Baseline 124.0 (92.0 to 187.5) 128.8 (98.0 to 157.0) 106.0 (80.0 to 149.0) 140.5 (92.5 to 177.5) 127.0 (95.8 to 169.3) 138.5 (103.5 to 176.0)
Week 12 127.0 (98.0 to 197.0) 117.0 (91.0 to 161.0) 101.0 (70.0 to 131.0) 99.0 (79.0 to 139.0) 124.5 (94.5 to 152.5) 127.5 (112.0 to 150.0)
% Change from baseline to week 12 9.7 (15.0 to 30.7) 6.6 (17.7 to 7.1) 5.5 (22.1 to 10.7) 18.9 (31.7 to6.1) 10.8 (25.4 to 13.3) 8.4 (21.5 to 10.1)
p Value‡ for % change with SAR236553 versus placebo 0.0987 0.0870 0.0006 0.0904 0.0533
Non–HDL-C, mg/dl
Baseline 160.0 28.9 149.5 29.4 150.4 30.1 151.8 34.6 157.5 22.8 159.2 28.5
Week 12 154.2 37.0 98.3 21.1 68.2 27.7 56.0 18.0 96.6 24.2 91.3 28.4
% Change from baseline to week 12, LS mean* (SE) 2.2 (2.9) 33.6 (2.9) 55.6 (2.9) 62.5 (3.0) 37.4 (3.0) 40.7 (2.9)
p Value* for % change with SAR236553 versus placebo 0.0001 0.0001 0.0001 0.0001 0.0001
Apo-B, mg/dl
Baseline 108.3 19.3 102.0 24.5 103.1 17.0 101.6 26.6 107.3 17.5 104.6 20.9
Week 12 109.2 27.0 73.0 16.4 54.0 18.4 44.1 14.1 74.9 17.1 68.6 20.3
% Change from baseline to week 12, LS mean* (SE) 2.2 (2.9) 27.3 (2.9) 48.1 (2.9) 56.1 (2.9) 28.7 (3.1) 33.1 (2.9)
p Value* for % change with SAR236553 versus placebo 0.0001 0.0001 0.0001 0.0001 0.0001
Apo-A1, g/l
Baseline 1.4 (1.3 to 1.6) 1.5 (1.4 to 1.7) 1.5 (1.4 to 1.7) 1.5 (1.3 to 1.7) 1.5 (1.3 to 1.7) 1.4 (1.3 to 1.6)
Week 12 1.4 (1.3 to 1.7) 1.6 (1.5 to 1.8) 1.5 (1.4 to 1.7) 1.6 (1.4 to 1.7) 1.5 (1.3 to 1.7) 1.5 (1.3 to 1.7)
% Change from baseline to week 12 0.0 (7.2 to 5.3) 1.4 (2.8 to 6.0) 0.3 (4.9 to 4.7) 1.4 (2.1 to 5.4) 1.5 (2.9 to 15.1) 4.2 (3.1 to 17.1)
p Value‡ for % change with SAR236553 versus placebo 0.0455 0.8713 0.1524 0.3019 0.0658
Lp(a), g/l
Baseline 0.2 (0.1 to 0.9) 0.2 (0.1 to 0.6) 0.3 (0.1 to 0.8) 0.3 (0.1 to 0.6) 0.3 (0.1 to 0.7) 0.2 (0.0 to 0.5)
Week 12 0.2 (0.07 to 0.85) 0.1 (0.04 to 0.43) 0.2 (0.08 to 0.71) 0.1 (0.05 to 0.41) 0.2 (0.06 to 0.73) 0.1 (0.02 to 0.44)
% Change from baseline to week 12 0.0 (11.8 to 11.5) 13.3 (33.3 to 0.0) 26.1 (36.7 to8.0) 28.6 (46.9 to22.2) 16.7 (33.3 to6.3) 7.9 (18.8 to 0.0)
p Value‡ for % change with SAR236553 versus placebo 0.0022 0.0001 0.0001 0.0006 0.0203
Values are mean  SD or median (Q1 to Q3). p Values for all parameters other than % change in LDL-C from baseline to week 12 are not adjusted for multiplicity and are included here for descriptive purposes only. *LS means and p values come from covariance analysis
with treatment group and randomization strata of atorvastatin dose as fixed effects and baseline as covariate. †Statistically significant p value according to hierarchical procedure. ‡ p Value comes from a rank analysis of covariance including terms for treatment,
randomization strata of atorvastatin dose, and baseline value. The treatment term had 2 levels: the considered SAR236553 dose and placebo.
Apo-A1  apolipoprotein-A1; Apo-B  apolipoprotein-B; HDL-C  high-density lipoprotein cholesterol; Lp(a), lipoprotein(a); LS  least squares; TC  total cholesterol; TG  triglycerides.
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June 19/26, 2012:2344–53 Safety and Efficacy of SAR236553/REGN727LDL-C across all treatment groups was similar at 123 to
132 mg/dl. SAR236553 demonstrated a clear dose-response
pattern in LDL-C lowering for both Q2W and Q4W
administration. Least squares mean  standard error reduc-
tions in LDL-C from baseline were 39.6  3.2% with 50
g Q2W, 64.2  3.1% with 100 mg Q2W, 72.4  3.2%
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Figure 3 Change in Calculated LDL-C From Baseline
to Week 12 by Stratified Atorvastatin Dose
Least squares (LS) mean (95% confidence interval [CI]) percentage change in
calculated low-density lipoprotein cholesterol (LDL-C) from baseline to week 12
in the modified intent-to-treat population, by treatment group and atorvastatin
dose. Abbreviations as in Figure 1.
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Figure 4 Change in Calculated LDL-C at 2-Week Intervals From
LS mean (SE) percentage change in calculated LDL-C from baseline to weeks 2,
by treatment group. Abbreviations as in Figures 1 and 3.ith 150 mg Q2W dose, 43.2  3.3% with 200 mg Q4W,
nd 47.7  3.2% with 300 mg Q4W, versus 5.1  3.1%
ith placebo. LDL-C reductions with SAR236553 were
imilar among atorvastatin doses (Fig. 3).
Figure 4 illustrates percentage LDL-C change at 2-week
ntervals. LDL-C reduction among placebo recipients
eached a maximum of 13.4% at week 6 and was 5.1% by
eek 12. LDL-C decreased significantly from baseline by
0.5%, 53.6%, and 62.9% at 2 weeks post-dosing with
AR236553 50 mg, 100 mg, and 150 mg Q2W, respec-
ively, with further reductions reaching 39.6%, 64.2%,
nd 72.4%, respectively, at week 12 (last observation carried
orward). For the 200- and 300-mg Q4W regimens, LDL-C
eductions achieved 2 weeks after the first dose were 66.8% and
9.5%, respectively, which waned over the succeeding 2 weeks
after administration of a placebo dose) to 38.6% and 53.4%,
espectively, at week 4. A similar pattern was observed with
ach subsequent 4-week dose, such that LDL-C reductions in
hese treatment arms appeared consistent at each 4-week
eriod.
econdary efficacy outcomes. Treatment effects on non-
DL lipid and Apo parameters are shown in Table 2.
otal cholesterol, non–HDL-C, and Apo-B decreased
ubstantially. Apo-B and non–HDL-C were reduced by
7% to 56% and 34% to 63%, respectively, and Lp(a) by
3% to 29% across SAR236553 Q2W regimens. Changes
n Apo-B and related lipids were proportional with the
Week 8 Week 10 Week 12 LOCF
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able and mostly small; the exception to this was the
150-mg Q2W regimen, which reduced triglycerides by
19%. Increases in both HDL-C and Apo-A1 were
variable, but greater with all SAR236553 regimens than
with placebo.
Eighty-nine percent to 100% versus 16% of SAR236553
versus placebo recipients achieved a target LDL-C of 100
mg/dl (Fig. 5). The LDL-C70 mg/dl target was achieved
by 47%, 84%, and 100% of 50-, 100-, and 150-mg Q2W
recipients, respectively, and by 46% and 57% of 200- and
300-mg Q4W recipients, versus 3% of placebo recipients.
At week 12, the Apo-B target of 80 mg/dl was achieved
by 67% to 100% and 59% to 77%, and the non–HDL-C
treatment target of 100 mg/dl by 60% to 100% and 54%
to 60% of patients assigned to 50 to 150 mg Q2W and 200
to 300 mg Q4W, respectively. Corresponding percentages
for placebo were 10% and 3%, respectively.
Safety. AEs were similar for all treatment groups, with no
dose relationship observed (Table 3).
Five serious AEs occurred in 4 patients during the study:
a 64-year-old placebo-treated male required back surgery; a
68-year-old female assigned to SAR236553 200 mg Q4W
underwent elective right knee total arthroplasty; a 69-year-
old female with a history of chronic obstructive pulmonary
disease, assigned to SAR236553 100 mg Q2W, was hospi-
talized during the follow-up period for worsening disease;
0
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(N = 31)
SAR 50 mg
Q2W (N = 30)
SAR 100
Q2W (N 
20 16.1
3.2
9.7
3.2
40
60
80
100
120
P
at
ie
nt
s 
A
ch
ie
vi
ng
 T
re
at
m
en
t T
ar
ge
t (
%
) 93.3
46.7
66.7
60
96.8
83.9
90
LDL-C <100 mg/dl (2.59 mmol/l)
LDL-C <70 mg/dl (1.81 mmol/l)
Figure 5 Attainment of Treatment Targets for LDL-C, Non–HDL-
The proportion of patients in each treatment arm achieving targets of: 100 mg/d
(LDL-C); 100 mg/dl (2.59 mmol/l) for non–high-density lipoprotein cholesterol (n
as in Figures 1 and 3.and a 57-year-old male who, after the initial dose of
SAR236553 300 mg Q4W, developed diarrhea followed by
a rash on his arms, legs, and abdomen, and was diagnosed
by biopsy with leukocytoclastic vasculitis. Prednisone treat-
ment led to full resolution. The investigator considered this
a significant medical event. No antidrug antibodies were
found following the event, but the week 20 follow-up
assessment found minimally detectable (titer of 30) anti-
drug antibodies. Blood samples obtained about 6 months
after the event were assessed for antinuclear antibodies,
tryptase, high-sensitivity C-reactive protein, and immuno-
globulin A, E, M, and G. The antinuclear antibody assess-
ments were negative, and all other results were within
normal limits. The same patient required surgery for a
humerus fracture that occurred during the follow-up period.
Six patients prematurely discontinued SAR236553 owing
to AEs: 1 each in the 100-mg Q2W (neutropenia) and
150-mg Q2W (fatigue) arms, 3 in the 200-mg Q4W arm
(injection-site rash, chest pain, and combined headache and
nausea), and 1 in the 300-mg Q4W arm (leukocytoclastic
vasculitis described earlier in the text). No AE-related
discontinuations occurred with placebo.
Mild injection-site reactions (this group term included
erythema, pruritis, swelling, discoloration, hematoma, and
rash) were the most common AEs (Table 3). These oc-
curred in SAR236553 recipients only, and were more
common with Q2W than Q4W dosing. Elevated creatine
SAR 150 mg
Q2W (N = 29)
SAR 200 mg
Q4W (N = 28)
SAR 300 mg
Q4W (N = 30)
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Apo-B <80 mg/dl (0.8 mmol/l)
Non-HDL-C <100 mg/dl (2.59 mmol/l)
d Apo-B
9 mmol/l) and 70 mg/dl (1.81 mmol/l) for low-density lipoprotein cholesterol
L-C); and 80 mg/dl (2.07 mmol/l) for apolipoprotein B (Apo-B). Abbreviations mg
= 31)
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June 19/26, 2012:2344–53 Safety and Efficacy of SAR236553/REGN727kinase10 ULN occurred in 1 patient (placebo-treated);
none had hepatic transaminases 3  ULN or significant
changes in other laboratory values. Muscle complaints were
infrequent and similar across treatment groups.
Discussion
This study demonstrated that SAR236553 is associated
with dose-related and dose regimen–dependent LDL-C
reductions in patients receiving stable atorvastatin therapy.
LDL-C reductions with 100 and 150 mg Q2W were
greater than with 200 and 300 mg Q4W at week 12, and
Summary of Treatment-Emergent Adverse Events (Safety PopulatioTable 3 Summary of Treatment-Emergent Adverse Events (Safe
Placebo
(n  31)
5
Overview of all TEAEs
Patients with any TEAE 14 (45.2)
Patients with any treatment-emergent SAE 1 (3.2)
Patients with any TEAE leading to death 0 (0.0)
Patients with any TEAE or treatment-emergent SAE leading
to permanent treatment discontinuation
0 (0.0)
AEs of special interest
ALT 3  ULN 0 (0.0)
AST 3  ULN 0 (0.0)
Muscle disorders (including pain, weakness) 1 (3.2)
CK 10  ULN 1 (3.2)
TEAEs occurring in 5% of patients in any treatment group
Sinusitis 3 (9.7)
Influenza 0 (0.0)
Nasopharyngitis 1 (3.2)
Upper respiratory tract infection 1 (3.2)
Urinary tract infection 0 (0.0)
Anemia 0 (0.0)
Headache 1 (3.2)
Bundle branch block left 2 (6.5)
Cough 1 (3.2)
Diarrhea 0 (0.0)
Nausea 2 (6.5)
Arthralgia 1 (3.2)
Back pain 0 (0.0)
Pain in extremity 1 (3.2)
Fatigue 0 (0.0)
Injection-site erythema 0 (0.0)
Injection-site pruritis 0 (0.0)
Injection-site swelling 0 (0.0)
Injection-site hematoma 0 (0.0)
Injection-site rash 0 (0.0)
Influenza-like illness 2 (6.5)
Elevated blood CK 2 (6.5)
Fall 0 (0.0)
Procedural pain 0 (0.0)
Values are n (%) and indicate the number and percentage of patients with at least 1 TEAE. Adverse
of the 30 patients randomized to SAR236553 200mg Q4Wwas not treated, and was therefore excl
arm, 1 in the 200-mg Q4W treatment arm, and 2 in the 300-mg Q4W treatment arm. For the safet
whereas the 2 patients in the 300-mg Q4W arm were switched to the 200-mg Q4W treatment ar
AE  adverse event; ALT  alanine aminotransferase; AST  aspartate aminotransferase; CK 
imit of normal.reached a maximum of 72% (150 mg Q2W). SAR236553150 mg Q2W reduced LDL-C to 70 mg/dl in 100% of
patients. The continued trend towards lower LDL-C ob-
served with multiple SAR236553 Q2W doses may indicate
a potential for further LDL-C reductions with longer
therapy duration. LDL-C reductions with SAR236553
were unaffected by atorvastatin dose (10, 20, or 40 mg
daily), suggesting that, although both statin and PCSK9
monoclonal antibody therapies up-regulate LDLRs, their
mechanisms of LDL-C reduction are independent. Further,
these agents appear to provide additive LDL-C–lowering
effects when administered in combination. LDL-C reduc-
pulation)
SAR236553
2W
0)
100 mg Q2W
(n  31)
150 mg Q2W
(n  31)
200 mg Q4W
(n  31)
300 mg Q4W
(N  28)
.0) 20 (64.5) 19 (61.3) 20 (64.5) 14 (50.0)
) 1 (3.2) 0 (0.0) 1 (3.2) 1 (3.6)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (3.2) 1 (3.2) 3 (9.7) 1 (3.6)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 0 (0.0) 0 (0,0) 0 (0.0) 0 (0.0)
) 2 (6.5) 1 (3.2) 1 (3.2) 2 (7.1)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (3.2) 2 (6.5) 1 (3.2) 0 (0.0)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
.3) 3 (9.7) 0 (0.0) 1 (3.2) 1 (3.6)
) 1 (3.2) 0 (0.0) 2 (6.5) 1 (3.6)
) 0 (0.0) 0 (0.0) 0 (0.0) 2 (7.1)
) 0 (0.0) 0 (0.0) 0 (0.0) 2 (7.1)
) 2 (6.5) 1 (3.2) 1 (3.2) 1 (3.6)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (3.2) 1 (3.2) 1 (3.2) 2 (7.1)
) 2 (6.5) 0 (0.0) 2 (6.5) 1 (3.6)
) 1 (3.2) 1 (3.2) 1 (3.2) 2 (7.1)
) 0 (0.0) 0 (0.0) 2 (6.5) 1 (3.6)
) 0 (0.0) 0 (0.0) 2 (6.5) 2 (7.1)
) 1 (3.2) 2 (6.5) 0 (0.0) 0 (0.0)
) 3 (9.7) 3 (9.7) 1 (3.2) 1 (3.6)
) 2 (6.5) 3 (9.7) 1 (3.2) 0 (0.0)
) 1 (3.2) 2 (6.5) 1 (3.2) 0 (0.0)
) 1 (3.2) 1 (3.2) 0 (0.0) 0 (0.0)
) 0 (0.0) 1 (3.2) 1 (3.2) 0 (0.0)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 0 (0.0) 2 (6.5) 0 (0.0) 0 (0.0)
) 0 (0.0) 1 (3.2) 1 (3.2) 2 (7.1)
) 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)
classified according to the Medical Dictionary of Regulatory Activities (MedDRA) Version 14.0. One
m the safety population. Four patients received an incorrect dose: 1 in the 100-mg Q2W treatment
ation, the patients on 100 mg Q2W and 200 mg Q4W were maintained in their respective groups,
g a total of 31 patients in the 200-mg Q4W arm.
ne kinase; SAE  serious adverse event; TEAE  treatment-emergent serious event; ULN  uppern)ty Po
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PCSK9 inhibition, and enhances the clearance of any
Apo-B–containing particles—including LDL, very-low-
density lipoprotein, and possibly, Lp(a). To our knowledge,
increasing LDLRs by combining SAR236553 with a statin
is not associated with any adverse effects.
Our findings suggest that patients who are unable to
achieve LDL-C treatment targets with statin monotherapy
may do so with the addition of SAR236553. Because
LDL-C increased after 2 weeks post-dosing, Q2W admin-
istration appears the most favorable dosing schedule.
SAR236553 100 and 150 mg Q2W reduced Apo-B by
48% and 56%, respectively, allowing 90% and 100% of
patients to achieve the 80 mg/dl Apo-B goal. Statin trials
indicate that no threshold exists, below which further
LDL-C reduction provides no additional benefit (25).
However, post hoc analyses of large outcomes trials suggest
that LDL-C does not represent the vascular burden of all
atherogenic lipoproteins, and that non–HDL-C and, even
more so, Apo-B levels may correlate better with outcomes
(3,26), especially in secondary cardiovascular disease prevention
and in high cardiometabolic risk patients (27,28). Adding
ezetimibe and/or bile acid sequestrants to statins further
reduces LDL-C by 12% to 18%, but reduces Apo-B by only
around 6%. This may account for the observed failure to reach
Apo-B targets when LDL-C goals are met (29). The potential
of SAR236553 to enable nearly all patients to attain both
LDL-C and Apo-B targets may thus offer an opportunity for
further cardiovascular risk reduction.
In this study, the effects of SAR236553 on triglycerides
were minimal; however, baseline triglyceride levels were
fairly low at 117 to 146 mg/dl. Statins, which also up-
regulate LDLR activity, similarly have little effect on trig-
lycerides in normotriglyceridemic patients (30). Very-low-
density lipoprotein particles are the principal carriers of
triglycerides. These particles contain Apo-B and are there-
fore subject to enhanced clearance as a result of LDLR
up-regulation by SAR236553. Thus, greater triglyceride
reductions would be expected in patients with higher baseline
triglycerides, and assessment of the true triglyceride-lowering
potential of SAR236553, with or without statins, will require
studies in patients with elevated baseline levels.
As in the earlier phase 1 trial (31), there was a trend
towards HDL-C and Apo-A1 increases with SAR236553
versus placebo. HDL-C may increase as a result of reduced
cholesteryl ester transfer protein–mediated transfer of cho-
lesterol from HDL to LDL or very-low-density lipoprotein,
owing to the reduction of LDL to very low levels. This
inability to transfer cholesterol from HDL leads to relative
increases in HDL-C, as evidenced by the minimal change in
Apo-A1, the major apolipoprotein in HDL.
The consistent, robust 13% to 29% Lp(a) reduction with
SAR236553 Q2W confirms phase 1 data showing similar
effects in SAR236553 patients receiving atorvastatin, but
not in those on diet alone (31). As the LDLR up-regulation
induced by statins, ezetimibe, and bile acid sequestrants hasno impact on Lp(a), it is possible that, with the large
LDL-C reductions, remaining competition from the
Apo-B on LDLR is minimal, enabling LDLR uptake of the
lower-affinity Apo-B on Lp(a). The actual mechanism of
Lp(a) reduction will require further study.
SAR236553 was well tolerated during this short study.
The frequency of injection-site reactions—which were gen-
erally mild, transient, and nonprogressive—requires much
larger, longer trials to determine clinical and compliance
impacts. There was no evidence of increasing clinical or
laboratory side effects with increasing SAR236553 dosage.
Specifically, this short study produced no evidence of
increases in either hepatic or muscle-related enzymes. The
occurrence of leukocytoclastic vasculitis in 1 patient 9 days
after initiation of SAR236553 300 mg was not associated
with other organ involvement, and the patient responded
rapidly to SAR236553 withdrawal and steroid therapy
initiation. No similar reactions were reported in prior
SAR236553 studies. Although the exact causality of the
leukocytoclastic vasculitis in this subject cannot be deter-
mined, it was deemed by the investigator to be SAR236553-
related. Again, larger, longer trials are required to determine
the frequency and severity of this potential side effect.
Leukocytoclastic vasculitis is a generally benign disease
that occurs in 40 to 60 individuals/million persons/year,
with drug therapy identified as the cause of about 20% of
cases (32). Numerous classes of agent have been implicated
in its development, including antibiotics and nonsteroidal
anti-inflammatory drugs (33), and leukocytoclastic vasculitis
is listed as an AE in the prescribing information for most
commercially available monoclonal antibody therapies. A
recent review of articles published between 1990 and 2008
reports 118 cases of cutaneous leukocytoclastic vasculitis in
patients receiving TNF monoclonal antibody therapy (34).
Our study is the largest and longest reported to date with
SAR236553, and included the most diverse patient popu-
lation. It confirms the finding of earlier proof-of-concept
trials that PCSK9 inhibition with monoclonal antibodies
robustly reduces levels of all Apo-B–containing atherogenic
lipoproteins, especially LDL-C. This effect was uniform,
irrespective of baseline atorvastatin dose, and greater sus-
tained efficacy was seen with Q2W dosing than with higher
doses given Q4W. The 72% LDL-C reduction with
SAR236553 150 mg Q2W surpasses that achieved with
almost any other lipid-lowering therapy. These encouraging
results suggest the need for further evaluation of
SAR236553 in larger, even more diverse patient popula-
tions, and with different background therapies, to fully
assess its efficacy and safety.
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